Literature DB >> 21649448

Assessing QT interval prolongation and its associated risks with antipsychotics.

Jimmi Nielsen1, Claus Graff, Jørgen K Kanters, Egon Toft, David Taylor, Jonathan M Meyer.   

Abstract

Several antipsychotics are associated with the ventricular tachycardia torsade de pointes (TdP), which may lead to sudden cardiac death (SCD), because of their inhibition of the cardiac delayed potassium rectifier channel. This inhibition extends the repolarization process of the ventricles of the heart, illustrated as a prolongation of the QT interval on a surface ECG. SCD in individuals receiving antipsychotics has an incidence of approximately 15 cases per 10,000 years of drug exposure but the exact association with TdP remains unknown because the diagnosis of TdP is uncertain. Most patients manifesting antipsychotic-associated TdP and subsequently SCD have well established risk factors for SCD, i.e. older age, female gender, hypokalaemia and cardiovascular disease. QT interval prolongation is the most widely used surrogate marker for assessing the risk of TdP but it is considered somewhat imprecise, partly because QT interval changes are subject to measurement error. In particular, drug-induced T-wave changes (e.g. flattening of the T-wave) may complicate the measurement of the QT interval. Furthermore, the QT interval depends on the heart rate and a corrected QT (QTc) interval is often used to compensate for this. Several correction formulas have been suggested, with Bazett's formula the most widely used. However, Bazett's formula overcorrects at a heart rate above 80 beats per minute and, therefore, Fridericia's formula is considered more appropriate to use in these cases. Several other surrogate markers for TdP have been developed but none of them is clinically implemented yet and QT interval prolongation is still considered the most valid surrogate marker. Although automated QT interval determination may offer some assistance, QT interval determination is best performed by a cardiologist skilled in its measurement. A QT interval >500 ms markedly increases the risk for TdP and SCD, and should lead to discontinuation of the offending drug and, if present, correction of underlying electrolyte disturbances, particularly serum potassium and magnesium derangements. Before prescribing antipsychotics that may increase the QTc interval, the clinician should ask about family and personal history of SCD, presyncope, syncope and cardiac arrhythmias, and recommend cardiology consultation if history is positive.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21649448     DOI: 10.2165/11587800-000000000-00000

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  99 in total

1.  Beat-to-beat QT dynamics in healthy subjects.

Authors:  Berit T Jensen; Charlotte E Larroude; Lars P Rasmussen; Niels-Henrik Holstein-Rathlou; Michael V Hojgaard; Erik Agner; Jørgen K Kanters
Journal:  Ann Noninvasive Electrocardiol       Date:  2004-01       Impact factor: 1.468

Review 2.  Errors and misconceptions in ECG measurement used for the detection of drug induced QT interval prolongation.

Authors:  Marek Malik
Journal:  J Electrocardiol       Date:  2004       Impact factor: 1.438

3.  Antipsychotic-associated all-cause and cardiac mortality: what should we worry about and how should the risk be assessed?

Authors:  Christoph U Correll; Jimmi Nielsen
Journal:  Acta Psychiatr Scand       Date:  2010-11       Impact factor: 6.392

4.  Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients.

Authors:  Jimmi Nielsen; Søren Skadhede; Christoph U Correll
Journal:  Neuropsychopharmacology       Date:  2010-06-02       Impact factor: 7.853

Review 5.  Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.

Authors:  A H Glassman; J T Bigger
Journal:  Am J Psychiatry       Date:  2001-11       Impact factor: 18.112

6.  The effect of sertindole on QTD and TPTE.

Authors:  J Nielsen; M P Andersen; C Graff; J K Kanters; T Hardahl; J Dybbro; J J Struijk; J M Meyer; E Toft
Journal:  Acta Psychiatr Scand       Date:  2010-01-19       Impact factor: 6.392

Review 7.  Prolonged QTc interval and risks of total and cardiovascular mortality and sudden death in the general population: a review and qualitative overview of the prospective cohort studies.

Authors:  Alicia Montanez; Jeremy N Ruskin; Patricia R Hebert; Gervasio A Lamas; Charles H Hennekens
Journal:  Arch Intern Med       Date:  2004-05-10

Review 8.  Physical illness and schizophrenia: a review of the literature.

Authors:  S Leucht; T Burkard; J Henderson; M Maj; N Sartorius
Journal:  Acta Psychiatr Scand       Date:  2007-11       Impact factor: 6.392

Review 9.  Cardiovascular risks of atypical antipsychotic drug treatment.

Authors:  Milou-Daniel Drici; Silvia Priori
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-08       Impact factor: 2.890

10.  Mechanism of the cardiotoxic actions of terfenadine.

Authors:  R L Woosley; Y Chen; J P Freiman; R A Gillis
Journal:  JAMA       Date:  1993 Mar 24-31       Impact factor: 56.272

View more
  33 in total

1.  Antipsychotics and the Risks of Sudden Cardiac Death and All-Cause Death: Cohort Studies in Medicaid and Dually-Eligible Medicaid-Medicare Beneficiaries of Five States.

Authors:  Charles E Leonard; Cristin P Freeman; Craig W Newcomb; Warren B Bilker; Stephen E Kimmel; Brian L Strom; Sean Hennessy
Journal:  J Clin Exp Cardiolog       Date:  2013

2.  T-wave morphology descriptors in patients with bulimia nervosa.

Authors:  Tomer Stahi; Keren Kaminer; Eitan Gur; Isaac Yao; Udi Nussinovitch
Journal:  Eat Weight Disord       Date:  2020-04-30       Impact factor: 4.652

Review 3.  Are the safety profiles of antipsychotic drugs used in dementia the same? An updated review of observational studies.

Authors:  Gianluca Trifiró; Janet Sultana; Edoardo Spina
Journal:  Drug Saf       Date:  2014-07       Impact factor: 5.606

4.  Need for a more developmental perspective: QTc prolongation under psychotropic medication.

Authors:  Veit Roessner; Nicole Wolff; Stefan Ehrlich; Robert Waltereit
Journal:  Eur Child Adolesc Psychiatry       Date:  2017-08       Impact factor: 4.785

5.  Minimal T-wave representation and its use in the assessment of drug arrhythmogenicity.

Authors:  Saeed Shakibfar; Claus Graff; Jørgen K Kanters; Jimmi Nielsen; Samuel Schmidt; Johannes J Struijk
Journal:  Ann Noninvasive Electrocardiol       Date:  2016-10-27       Impact factor: 1.468

6.  Mandatory electrocardiographic monitoring in young patients treated with psychoactive drugs.

Authors:  Renata Rizzo; Mariangela Gulisano; Paola V Calì; Alfredo Di Pino
Journal:  Eur Child Adolesc Psychiatry       Date:  2013-04-04       Impact factor: 4.785

7.  Quetiapine-induced Bradycardia and Hypotension in the Elderly-A Case Report.

Authors:  Masaru Nakamura; Megumi Seki; Yosuke Sato; Takahiko Nagamine
Journal:  Innov Clin Neurosci       Date:  2016-02-01

8.  Treating an Adolescent with Long QT Syndrome for Bipolar Disorder: A Case Presentation.

Authors:  Özlem Önen; Ayşe Kutlu; Handan Özek Erkuran
Journal:  Psychopharmacol Bull       Date:  2017-01-26

9.  Frequency of use of QT-interval prolonging drugs in psychiatry in Belgium.

Authors:  Eline Vandael; Thomas Marynissen; Johan Reyntens; Isabel Spriet; Joris Vandenberghe; Rik Willems; Veerle Foulon
Journal:  Int J Clin Pharm       Date:  2014-05-08

10.  Electrocardiograms changes in children with functional gastrointestinal disorders on low dose amitriptyline.

Authors:  Ashish Chogle; Miguel Saps
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.